JP2018533954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533954A5 JP2018533954A5 JP2018524194A JP2018524194A JP2018533954A5 JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5 JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018524194 A JP2018524194 A JP 2018524194A JP 2018533954 A5 JP2018533954 A5 JP 2018533954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- expression
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194367 | 2015-11-12 | ||
| EP15194367.7 | 2015-11-12 | ||
| EP16189502.4 | 2016-09-19 | ||
| EP16189502 | 2016-09-19 | ||
| PCT/EP2016/077383 WO2017081223A1 (en) | 2015-11-12 | 2016-11-11 | Oligonucleotides for inducing paternal ube3a expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020136397A Division JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533954A JP2018533954A (ja) | 2018-11-22 |
| JP2018533954A5 true JP2018533954A5 (enExample) | 2020-04-09 |
| JP6751142B2 JP6751142B2 (ja) | 2020-09-02 |
Family
ID=57345910
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
| JP2018524194A Active JP6751142B2 (ja) | 2015-11-12 | 2016-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521433A Expired - Fee Related JP7066609B2 (ja) | 2015-11-12 | 2016-11-11 | 霊長類種に由来する標準化された神経細胞アッセイ |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521350A Pending JP2018533362A (ja) | 2015-11-12 | 2016-11-11 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2020136397A Active JP7279000B2 (ja) | 2015-11-12 | 2020-08-12 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2021113496A Pending JP2021191262A (ja) | 2015-11-12 | 2021-07-08 | 薬物候補の有効性プロファイルを決定するための方法 |
| JP2023009553A Pending JP2023052630A (ja) | 2015-11-12 | 2023-01-25 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
| JP2024196762A Pending JP2025024060A (ja) | 2015-11-12 | 2024-11-11 | 父方ｕｂｅ３ａの発現を誘導するオリゴヌクレオチド |
Country Status (30)
| Country | Link |
|---|---|
| US (10) | US10494633B2 (enExample) |
| EP (5) | EP3374499A1 (enExample) |
| JP (7) | JP7066609B2 (enExample) |
| KR (4) | KR20250121139A (enExample) |
| CN (5) | CN116064540A (enExample) |
| AU (4) | AU2016352836B2 (enExample) |
| CA (1) | CA3004799C (enExample) |
| CL (3) | CL2018001189A1 (enExample) |
| CO (1) | CO2018004550A2 (enExample) |
| CR (3) | CR20180264A (enExample) |
| DK (2) | DK3374509T3 (enExample) |
| ES (2) | ES2852998T4 (enExample) |
| FI (1) | FI4220360T3 (enExample) |
| HK (2) | HK1258309A1 (enExample) |
| HR (2) | HRP20241138T1 (enExample) |
| HU (2) | HUE067905T2 (enExample) |
| IL (4) | IL281211B2 (enExample) |
| LT (2) | LT3374509T (enExample) |
| MA (1) | MA67580B1 (enExample) |
| MX (4) | MX2018004978A (enExample) |
| PE (2) | PE20210451A1 (enExample) |
| PH (1) | PH12018501005A1 (enExample) |
| PL (2) | PL4220360T3 (enExample) |
| RS (2) | RS61529B9 (enExample) |
| RU (1) | RU2742007C2 (enExample) |
| SG (1) | SG11201803951QA (enExample) |
| SI (2) | SI3374509T1 (enExample) |
| UA (1) | UA125963C2 (enExample) |
| WO (3) | WO2017081223A1 (enExample) |
| ZA (1) | ZA201802494B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| MX342945B (es) | 2009-07-06 | 2016-10-18 | Ontorii Inc * | Profármacos de ácido nucleico novedosos y métodos de uso de los mismos. |
| NZ599032A (en) | 2009-09-11 | 2014-09-26 | Isis Pharmaceuticals Inc | Modulation of huntingtin expression |
| DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| US9605019B2 (en) | 2011-07-19 | 2017-03-28 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| KR20240148947A (ko) | 2012-07-13 | 2024-10-11 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| US10400243B2 (en) | 2014-11-25 | 2019-09-03 | Ionis Pharmaceuticals, Inc. | Modulation of UBE3A-ATS expression |
| IL281211B2 (en) | 2015-11-12 | 2024-01-01 | Hoffmann La Roche | Oligonucleotides for inducing paternal ube3a expression |
| HRP20250804T1 (hr) | 2017-12-01 | 2025-09-12 | The Texas A&M University System | Antisense liječenje angelmanovog sindroma |
| AU2019218987B2 (en) | 2018-02-12 | 2025-04-24 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
| CA3113648A1 (en) * | 2018-09-21 | 2020-03-26 | University Of Connecticut | Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome |
| EP3911957A1 (en) | 2019-01-17 | 2021-11-24 | F. Hoffmann-La Roche AG | E3 ubiquitin ligase (ube3a) protein targets |
| CN113490742A (zh) * | 2019-02-20 | 2021-10-08 | 罗氏创新中心哥本哈根有限公司 | 膦酰基乙酸酯缺口聚物寡核苷酸 |
| MD3947684T2 (ro) * | 2019-03-29 | 2025-10-31 | Ionis Pharmaceuticals Inc | Compuși și metode pentru modularea UBE3A-ATS |
| AU2020279387A1 (en) * | 2019-05-22 | 2021-12-09 | The University Of North Carolina At Chapel Hill | UBE3A genes and expression cassettes and their use |
| CN113874494A (zh) | 2019-05-28 | 2021-12-31 | 豪夫迈·罗氏有限公司 | 产生单核细胞祖细胞的方法 |
| TW202204607A (zh) * | 2020-04-16 | 2022-02-01 | 英商羅斯林科技有限公司 | 誘導性多功能幹細胞(iPSC)之誘導 |
| US20230212572A1 (en) * | 2020-06-09 | 2023-07-06 | Roche Innovation Center Copenhagen A/S | Guanosine Analogues for Use in Therapeutics Polynucleotides |
| EP4282651A4 (en) | 2021-01-21 | 2024-12-18 | Fujimori Kogyo Co., Ltd. | MULTILAYER FILM AND PACKAGING BAGS |
| CN119173632A (zh) | 2022-05-10 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 靶向cfp-elk1基因间区域的反义寡核苷酸 |
| EP4705457A2 (en) | 2023-05-04 | 2026-03-11 | F. Hoffmann-La Roche AG | Oligonucleotides capable of upregulating glucocerebrosidase expression |
| KR20250068540A (ko) * | 2023-11-08 | 2025-05-16 | 한국과학기술원 | Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도 |
| WO2025125542A1 (en) | 2023-12-15 | 2025-06-19 | F. Hoffmann-La Roche Ag | Intrathecal dosage method |
| WO2025213123A1 (en) * | 2024-04-05 | 2025-10-09 | Encoded Therapeutics, Inc. | Methods and compositions for increasing expression of ube3a |
| TW202548015A (zh) * | 2024-04-11 | 2025-12-16 | 美商奧崔基尼克斯製藥公司 | 天使症候群反義治療的給藥方案 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4373084A (en) | 1981-07-07 | 1983-02-08 | E. I. Du Pont De Nemours And Company | Sulfur-modified polypropylene ether glycols, a method for preparing them, and polyurethanes prepared therefrom |
| ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| DE69829760T3 (de) | 1997-09-12 | 2016-04-14 | Exiqon A/S | Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga |
| US6238921B1 (en) | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| KR100573231B1 (ko) | 1999-02-12 | 2006-04-24 | 상꾜 가부시키가이샤 | 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체 |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| EP1234174A1 (en) | 1999-12-02 | 2002-08-28 | Myriad Genetics, Inc. | Protein-protein interactions |
| US6300132B1 (en) | 1999-12-17 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Antisense inhibition of telomeric repeat binding factor 2 expression |
| AU2001268163A1 (en) * | 2000-06-01 | 2001-12-11 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ube3a gene |
| US20030087855A1 (en) | 2001-09-13 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of protein kinase R expression |
| CA2451643C (en) * | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
| US20050124572A1 (en) | 2002-06-17 | 2005-06-09 | Freier Susan M. | Compositions and their uses directed to signal tranducers |
| WO2004016754A2 (en) | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
| WO2004028458A2 (en) * | 2002-09-25 | 2004-04-08 | Pharmacia Corporation | Antisense modulation of microsomal prostaglandin e2 synthase expression |
| EP2752488B1 (en) | 2002-11-18 | 2020-02-12 | Roche Innovation Center Copenhagen A/S | Antisense design |
| KR20060115351A (ko) | 2003-08-29 | 2006-11-08 | 위스콘신 얼럼나이 리서어치 화운데이션 | 영장류 배아 줄기 세포 기원의 신경 줄기 세포, 운동 뉴런및 도파민 뉴런의 시험관내 분화 방법 |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
| CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| CA3044969A1 (en) | 2006-05-05 | 2007-12-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ， インコーポレーテッド | ５’修飾二環式核酸類似体 |
| US8580756B2 (en) | 2007-03-22 | 2013-11-12 | Santaris Pharma A/S | Short oligomer antagonist compounds for the modulation of target mRNA |
| PE20090064A1 (es) | 2007-03-26 | 2009-03-02 | Novartis Ag | Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| CN101796062B (zh) | 2007-07-05 | 2014-07-30 | Isis制药公司 | 6-双取代双环核酸类似物 |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| WO2010096496A2 (en) * | 2009-02-17 | 2010-08-26 | Memorial Sloan-Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| WO2011017521A2 (en) | 2009-08-06 | 2011-02-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| AU2010306377B2 (en) | 2009-10-13 | 2015-01-22 | Stemcell Technologies Canada Inc. | Manipulation of osmolality for differentiating stem cells |
| KR101891352B1 (ko) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | 간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료 |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| CA2805318A1 (en) | 2010-07-14 | 2012-01-19 | Curna, Inc. | Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg |
| US20130225659A1 (en) | 2010-07-19 | 2013-08-29 | Isis Pharmaceuticals, Inc. | Modulation of nuclear-retained rna |
| KR20160033798A (ko) * | 2010-08-19 | 2016-03-28 | 에프. 호프만-라 로슈 아게 | 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (ｉｒｎｓｃｓ) 로의 전환 |
| WO2012064806A2 (en) | 2010-11-11 | 2012-05-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for unsilencing imprinted genes |
| WO2012068405A2 (en) | 2010-11-17 | 2012-05-24 | Isis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2012135621A2 (en) | 2011-03-30 | 2012-10-04 | Cellular Dynamics International. Inc | Priming of pluripotent stem cells for neural differentiation |
| KR20140031217A (ko) | 2011-04-20 | 2014-03-12 | 로슈 글리카트 아게 | 혈액-뇌 차단벽의 pH 의존적 통과를 위한 방법 및 구축물 |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| CA2863253A1 (en) | 2011-09-07 | 2013-03-14 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| ES2809199T3 (es) * | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| JP6452614B2 (ja) | 2012-11-15 | 2019-01-16 | ロシュ イノベーション センター コペンハーゲン エーエス | オリゴヌクレオチドコンジュゲート |
| WO2014077693A1 (en) | 2012-11-16 | 2014-05-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for reducing an effect of aging in a mammalian cell |
| US9694036B2 (en) | 2014-03-21 | 2017-07-04 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
| IL281211B2 (en) | 2015-11-12 | 2024-01-01 | Hoffmann La Roche | Oligonucleotides for inducing paternal ube3a expression |
| RU2019143627A (ru) | 2017-06-28 | 2021-07-28 | Юниверсити Оф Соус Флорида | Модифицированный ген ube3a для генной терапии синдрома ангельмана |
| HRP20250804T1 (hr) | 2017-12-01 | 2025-09-12 | The Texas A&M University System | Antisense liječenje angelmanovog sindroma |
| JP7383618B2 (ja) | 2018-01-26 | 2023-11-20 | エフ． ホフマン－ラ ロシュ アーゲー | 放射標識オリゴヌクレオチドおよびその調製のための方法 |
| MD3947684T2 (ro) | 2019-03-29 | 2025-10-31 | Ionis Pharmaceuticals Inc | Compuși și metode pentru modularea UBE3A-ATS |
-
2016
- 2016-11-11 IL IL281211A patent/IL281211B2/en unknown
- 2016-11-11 KR KR1020257024980A patent/KR20250121139A/ko active Pending
- 2016-11-11 KR KR1020227045154A patent/KR102840652B1/ko active Active
- 2016-11-11 EP EP16798672.8A patent/EP3374499A1/en not_active Withdrawn
- 2016-11-11 PL PL23152543.7T patent/PL4220360T3/pl unknown
- 2016-11-11 WO PCT/EP2016/077383 patent/WO2017081223A1/en not_active Ceased
- 2016-11-11 KR KR1020187013292A patent/KR102185465B1/ko active Active
- 2016-11-11 HR HRP20241138TT patent/HRP20241138T1/hr unknown
- 2016-11-11 WO PCT/EP2016/077429 patent/WO2017081250A1/en not_active Ceased
- 2016-11-11 RU RU2018119315A patent/RU2742007C2/ru active
- 2016-11-11 LT LTEP16798440.0T patent/LT3374509T/lt unknown
- 2016-11-11 CA CA3004799A patent/CA3004799C/en active Active
- 2016-11-11 CN CN202211275978.XA patent/CN116064540A/zh active Pending
- 2016-11-11 DK DK16798440.0T patent/DK3374509T3/da active
- 2016-11-11 SI SI201631093T patent/SI3374509T1/sl unknown
- 2016-11-11 HK HK19100676.0A patent/HK1258309A1/zh unknown
- 2016-11-11 UA UAA201806476A patent/UA125963C2/uk unknown
- 2016-11-11 MA MA67580A patent/MA67580B1/fr unknown
- 2016-11-11 CR CR20180264A patent/CR20180264A/es unknown
- 2016-11-11 AU AU2016352836A patent/AU2016352836B2/en active Active
- 2016-11-11 CN CN201680066253.6A patent/CN108291226B/zh active Active
- 2016-11-11 KR KR1020207033999A patent/KR102482440B1/ko active Active
- 2016-11-11 RS RS20210241A patent/RS61529B9/sr unknown
- 2016-11-11 WO PCT/EP2016/077435 patent/WO2017081254A1/en not_active Ceased
- 2016-11-11 SI SI201631843T patent/SI4220360T1/sl unknown
- 2016-11-11 JP JP2018521433A patent/JP7066609B2/ja not_active Expired - Fee Related
- 2016-11-11 CR CR20220077A patent/CR20220077A/es unknown
- 2016-11-11 PE PE2020000810A patent/PE20210451A1/es unknown
- 2016-11-11 EP EP20204481.4A patent/EP3798307A1/en active Pending
- 2016-11-11 RS RS20241003A patent/RS66036B1/sr unknown
- 2016-11-11 ES ES16798440T patent/ES2852998T4/es active Active
- 2016-11-11 EP EP23152543.7A patent/EP4220360B9/en active Active
- 2016-11-11 CN CN202211275954.4A patent/CN116064539A/zh active Pending
- 2016-11-11 JP JP2018524194A patent/JP6751142B2/ja active Active
- 2016-11-11 SG SG11201803951QA patent/SG11201803951QA/en unknown
- 2016-11-11 CR CR20200118A patent/CR20200118A/es unknown
- 2016-11-11 EP EP16798440.0A patent/EP3374509B1/en active Active
- 2016-11-11 PE PE2018000752A patent/PE20181157A1/es unknown
- 2016-11-11 IL IL300119A patent/IL300119B1/en unknown
- 2016-11-11 LT LTEP23152543.7T patent/LT4220360T/lt unknown
- 2016-11-11 ES ES23152543T patent/ES2991800T3/es active Active
- 2016-11-11 HR HRP20210227TT patent/HRP20210227T1/hr unknown
- 2016-11-11 JP JP2018521350A patent/JP2018533362A/ja active Pending
- 2016-11-11 DK DK23152543.7T patent/DK4220360T3/da active
- 2016-11-11 EP EP16797824.6A patent/EP3374498A1/en not_active Withdrawn
- 2016-11-11 PL PL16798440T patent/PL3374509T3/pl unknown
- 2016-11-11 HU HUE23152543A patent/HUE067905T2/hu unknown
- 2016-11-11 FI FIEP23152543.7T patent/FI4220360T3/fi active
- 2016-11-11 HU HUE16798440A patent/HUE053197T2/hu unknown
- 2016-11-11 CN CN201680065987.2A patent/CN108350431A/zh active Pending
- 2016-11-11 CN CN201680066009.XA patent/CN108350432A/zh active Pending
- 2016-11-11 MX MX2018004978A patent/MX2018004978A/es unknown
- 2016-11-11 HK HK19100670.6A patent/HK1258434A1/zh unknown
- 2016-11-14 US US15/351,113 patent/US10494633B2/en active Active
-
2018
- 2018-04-03 IL IL258488A patent/IL258488B/en active IP Right Grant
- 2018-04-16 ZA ZA2018/02494A patent/ZA201802494B/en unknown
- 2018-04-23 MX MX2022016376A patent/MX2022016376A/es unknown
- 2018-04-23 MX MX2022016381A patent/MX2022016381A/es unknown
- 2018-04-23 MX MX2022016377A patent/MX2022016377A/es unknown
- 2018-04-26 CO CONC2018/0004550A patent/CO2018004550A2/es unknown
- 2018-05-03 CL CL2018001189A patent/CL2018001189A1/es unknown
- 2018-05-08 PH PH12018501005A patent/PH12018501005A1/en unknown
- 2018-05-11 US US15/977,970 patent/US20190154664A1/en not_active Abandoned
- 2018-05-11 US US15/977,895 patent/US20190144824A1/en not_active Abandoned
-
2019
- 2019-04-18 US US16/388,714 patent/US10739332B2/en active Active
- 2019-10-24 US US16/663,024 patent/US10718753B2/en active Active
-
2020
- 2020-04-02 CL CL2020000889A patent/CL2020000889A1/es unknown
- 2020-05-29 AU AU2020203573A patent/AU2020203573B2/en active Active
- 2020-07-20 US US16/933,445 patent/US11320421B2/en active Active
- 2020-08-12 JP JP2020136397A patent/JP7279000B2/ja active Active
-
2021
- 2021-07-08 JP JP2021113496A patent/JP2021191262A/ja active Pending
- 2021-08-13 CL CL2021002159A patent/CL2021002159A1/es unknown
-
2022
- 2022-01-21 US US17/581,089 patent/US11852627B2/en active Active
- 2022-08-05 AU AU2022211910A patent/AU2022211910B2/en active Active
-
2023
- 2023-01-25 JP JP2023009553A patent/JP2023052630A/ja active Pending
- 2023-01-25 AU AU2023200410A patent/AU2023200410B2/en active Active
- 2023-02-22 US US18/172,707 patent/US12259380B2/en active Active
- 2023-10-20 US US18/491,513 patent/US12566172B2/en active Active
-
2024
- 2024-11-11 JP JP2024196762A patent/JP2025024060A/ja active Pending
-
2025
- 2025-07-02 US US19/258,035 patent/US20250389713A1/en active Pending
- 2025-12-10 IL IL325248A patent/IL325248A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018533954A5 (enExample) | ||
| HRP20210227T1 (hr) | Oligonukleotidi za indukciju ekspresije paternalnog gena ube3a | |
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| WO2013074974A3 (en) | Modified rnai agents | |
| JP2018519835A5 (enExample) | ||
| BR112013010525A2 (pt) | tratamento de hbv | |
| JP2015516989A5 (enExample) | ||
| BR112015022876A2 (pt) | agente, composição farmacêutica e método para inibição da expressão do componente do complemento c5, uso do referido agente, vetor e célula. | |
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2018530530A5 (enExample) | ||
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112015021470A2 (pt) | conjugado de polímero para administração de um agente bioativo | |
| PE20210668A1 (es) | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales | |
| BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
| MX2020005680A (es) | Tratamiento antisentido del sindrome de angelman. | |
| CL2013003105A1 (es) | Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer | |
| JP2016520310A5 (enExample) | ||
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| JP2021500016A5 (enExample) | ||
| JP2011515357A5 (enExample) | ||
| WO2013162350A3 (en) | Circular antiviral rna | |
| JP2011519365A5 (enExample) | ||
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos |